Back to Journals » Breast Cancer: Targets and Therapy » Volume 3

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women

Authors Patil AW, Singhai R, Bhamre RS, Tayade MBT, Patil VW

Published 19 April 2011 Volume 2011:3 Pages 27—33

DOI https://doi.org/10.2147/BCTT.S17892

Review by Single-blind

Peer reviewer comments 2

This paper has been retracted.
 
Amit V Patil1, Rahul S Bhamre2, Rajeev Singhai3, Mukund B Tayade4, Vinayak W Patil3
1Department of General Surgery, Government Medical College, Miraj, Maharashtra, India; 2Department of General Surgery, DY Patil Hospital and Research Centre, Nerul, Navi Mumbai, India; 3Department of Biochemistry, Grant Medical College and Sir JJ Group of Hospitals Mumbai, India; 4Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals Mumbai, India

Objective: To determine the expressions and relationship between estrogen receptors (ERs) and progesterone receptors (PgRs) in breast cancer in Indian women.
Participants: Surgically removed breast cancer tissues were collected from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, taking (n = 300) cases of infiltrating duct cancer of Indian women after radical mastectomy and lumpectomy; the age- and menopausal-related subgroups satisfied this requirement.
Measurements: Statistical significance was calculated by the likelihood ratio test; relative risk served to check for significant differences. Relapse-free interval probabilities were calculated according to Kaplan and Meier, with Cox–Mantel test comparing survival functions and P values.
Results: We observed that only in middle-aged postmenopausal patients bearing pT2 tumors were ER and PgR receptors shown to have a prognostic significance with the lowest tested cutoff value being 5 fmol/mg.
Conclusion: Immunohistochemistry analysis has been shown to be a prognostic factor for patients with breast cancer; the major aim of determining the ER receptor status is to assess predictive response to hormonal therapy.

Keywords: prognostic cancer tissue biomarkers, immunohistochemistry, hormone receptors, steroid receptors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]